JPWO2021107122A1 - - Google Patents

Info

Publication number
JPWO2021107122A1
JPWO2021107122A1 JP2021561565A JP2021561565A JPWO2021107122A1 JP WO2021107122 A1 JPWO2021107122 A1 JP WO2021107122A1 JP 2021561565 A JP2021561565 A JP 2021561565A JP 2021561565 A JP2021561565 A JP 2021561565A JP WO2021107122 A1 JPWO2021107122 A1 JP WO2021107122A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021561565A
Other versions
JP7280470B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021107122A1 publication Critical patent/JPWO2021107122A1/ja
Application granted granted Critical
Publication of JP7280470B2 publication Critical patent/JP7280470B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021561565A 2019-11-29 2020-11-27 特定アミノ酸またはアミノ酸様物質による低酸素応答制御 Active JP7280470B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019216993 2019-11-29
JP2019216993 2019-11-29
PCT/JP2020/044297 WO2021107122A1 (ja) 2019-11-29 2020-11-27 特定アミノ酸またはアミノ酸様物質による低酸素応答制御

Publications (2)

Publication Number Publication Date
JPWO2021107122A1 true JPWO2021107122A1 (ja) 2021-06-03
JP7280470B2 JP7280470B2 (ja) 2023-05-24

Family

ID=76129619

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021561565A Active JP7280470B2 (ja) 2019-11-29 2020-11-27 特定アミノ酸またはアミノ酸様物質による低酸素応答制御

Country Status (2)

Country Link
JP (1) JP7280470B2 (ja)
WO (1) WO2021107122A1 (ja)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008517943A (ja) * 2004-10-25 2008-05-29 ザ ヘンリー エム ジャクソン ファウンデーション Ｈｉｆ−１媒介遺伝子発現を低下させる方法
JP2009249335A (ja) * 2008-04-04 2009-10-29 Takahashi Gakuen 脳血管性認知症の治療剤および該治療剤を含有する飲食物、補助食品
KR20100006601A (ko) * 2008-07-10 2010-01-21 강릉원주대학교산학협력단 고등어 분획 건조 분말 또는 그 추출물을 유효성분으로함유하는 산화 관련 질환의 예방 및 치료용 조성물
JP2018087174A (ja) * 2016-11-30 2018-06-07 微小循環研究所 有限会社 認知機能障害改善用組成物。

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008517943A (ja) * 2004-10-25 2008-05-29 ザ ヘンリー エム ジャクソン ファウンデーション Ｈｉｆ−１媒介遺伝子発現を低下させる方法
JP2009249335A (ja) * 2008-04-04 2009-10-29 Takahashi Gakuen 脳血管性認知症の治療剤および該治療剤を含有する飲食物、補助食品
KR20100006601A (ko) * 2008-07-10 2010-01-21 강릉원주대학교산학협력단 고등어 분획 건조 분말 또는 그 추출물을 유효성분으로함유하는 산화 관련 질환의 예방 및 치료용 조성물
JP2018087174A (ja) * 2016-11-30 2018-06-07 微小循環研究所 有限会社 認知機能障害改善用組成物。

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AMANO, H ET AL.: "Target validation in hypoxia-induced vascular remodeling using transcriptome/metabolome analysis", THE PHARMACOGENOMICS JOURNAL, vol. Vol. 3, Issue 3, JPN6020049324, 2003, pages 183 - 188, ISSN: 0004996426 *
TORII, SATORU ET AL.: "Inhibitory effect of extracellular histidine on cobalt-induced HIF-1a expression", J. BIOCHEM., vol. Vol. 149, Issue 2, JPN6020049325, 2011, pages 171 - 176, ISSN: 0004996427 *
ZHENG, JUN-YI ET AL.: "Influence of taurine on expression level of hypoxia induction factor-1α in hypoxia-injured rat card", CHIN J GERIATR HEART BRAIN VESSEL DIS, vol. 12, no. 6, JPN6020049323, 2010, pages 545 - 547, ISSN: 0004996425 *
日本食生活学会誌, vol. 10, no. 3, JPN6023006798, 1999, pages 81 - 100, ISSN: 0004996428 *

Also Published As

Publication number Publication date
WO2021107122A1 (ja) 2021-06-03
JP7280470B2 (ja) 2023-05-24

Similar Documents

Publication Publication Date Title
BR112019017762A2 (ja)
BR112021013854A2 (ja)
BR112021018450A2 (ja)
BR112021017939A2 (ja)
BR112021017892A2 (ja)
BR112019016141A2 (ja)
BR112019016142A2 (ja)
BR112019016138A2 (ja)
BR112021018168A2 (ja)
AU2020104490A5 (ja)
BR112021008711A2 (ja)
BR112021018452A2 (ja)
BR112021018102A2 (ja)
BR112021018584A2 (ja)
BR112021015080A2 (ja)
BR112021012348A2 (ja)
BR112021018250A2 (ja)
BR112021018093A2 (ja)
BR112021018084A2 (ja)
BR112021013944A2 (ja)
BR112021013128A2 (ja)
BR112021018484A2 (ja)
BR112021016205A2 (ja)
BR112019016136A2 (ja)
BR112021016821A2 (ja)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211216

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20220307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230323

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230421

R150 Certificate of patent or registration of utility model

Ref document number: 7280470

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04